Clinical Trials Browser

Interventional × Squamous Cell Carcinoma of Head and Neck × VTX-2337 × Clear all

NCT04272333 2022-04-14

Intratumoral Microdosing of Motolimod in HNSCC

Phase EARLY_PHASE1 Terminated

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT01836029 2019-10-29

Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 2 Completed

195 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck

NCT02124850 2019-10-25

A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab

Phase 1 Terminated

Squamous Cell Carcinoma of Head and Neck

NCT01334177 2015-03-05

TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck

Phase 1 Completed

Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms